Journal
CURRENT ONCOLOGY REPORTS
Volume 13, Issue 6, Pages 459-471Publisher
SPRINGER
DOI: 10.1007/s11912-011-0199-3
Keywords
Ovarian carcinoma; CA125; Surgery; Radiotherapy; Follow up; Platinum-free intervals; Platinum hypersensitivity; Chemotherapy; Antiangiogenesis; PARP inhibitors; Hormones; Tyrosine kinase inhibitors
Categories
Ask authors/readers for more resources
Notwithstanding continuing efforts to improve the primary treatment for ovarian cancer, most patients will ultimately develop recurrent disease. The benefits of detection and early systemic treatment of recurrence are now in doubt following the presentation of the MRC/EORTC CA125 surveillance trial. The impact of secondary cytoreductive surgery on survival requires more investigation. The role of antiangiogenic and other biological agents such as PARP inhibitors is becoming increasingly important for patients as an addition or alternative to the more conventional cytotoxic therapies available. Uncertainties and choices abound both in the treatment of recurrent ovarian cancer and the timing of such interventions. This article not only explores how to treat these patients but also the controversial issue of when to treat. Educating and involving the patient in decisions about their treatment options is of paramount importance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available